SeqOIA is one of of the two national high throughput sequencing platforms selected within the framework of the Plan France médecine génomique 2025 (the French initiative for genomic medicine – led by AVIESAN) set up to ensure that everyone has access to new technologies in genomic medicine in an equitable manner throughout the country. SeqOIA’s mission is to allow equal access for all to genomic analyses so that cancer, rare disease, or common disease patients can benefit from the latest predictive and personalised medicine breakthroughs.
High throughput sequencing platforms, consisting of
* Analysis platform (SeqOIA-Gen) for qualification, extraction, preparation and sequencing
* Bioinformatics platform (SeqOIA-IT) for data processing, storage, archiving
* Interpretation platform (SeqOIA-LMG): brings together the expert biologists from the Genomic Medicine Laboratories (LMG) who will validate the reports of the medical analyzes of the SeqOIA Medical Biology laboratory (LBM SeqOIA).
